PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

Introduction [ 177 Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging treatment option for patients with end-stage prostate cancer. However, response to Lu-PSMA therapy is only achieved in approximately half of patients. It is clinically important to identify patients at risk of poor outcom...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of nuclear medicine and molecular imaging 2021-04, Vol.48 (4), p.1200-1210
Hauptverfasser:	Seifert, Robert, Kessel, Katharina, Schlack, Katrin, Weber, Manuel, Herrmann, Ken, Spanke, Maximilian, Fendler, Wolfgang P., Hadaschik, Boris, Kleesiek, Jens, Schäfers, Michael, Weckesser, Matthias, Boegemann, Martin, Rahbar, Kambiz
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiology Imaging Lesions Lutetium isotopes Medicine Medicine & Public Health Nuclear Medicine Oncology Oncology – Genitourinary Original Original Article Orthopedics Positron emission tomography Prostate cancer Quotients Radiology Regression analysis Statistical analysis Survival Therapy Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!